- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04828226
Clonidine to Prevent Delirium After Electroconvulsive Therapy. (ECaTa)
Clonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Electroconvulsive therapy (ECT) is a highly efficacious therapy for psychiatric disorders, especially major depressive disorder, bipolar disorder and catatonia resistant to psychopharmacology or drug-psychotherapy combination therapy. At therapy induction, usually a series of 10-12 ECT sessions is planned with two to three days in between sessions. Thereafter, maintenance therapy can be continued with longer session intervals thereafter to avoid relapses and to support further drug and psychotherapy treatment. Without maintenance therapy, relapses can happen in up to 80% of all patients within one year.
Nowadays conducted under general anaesthesia (etomidate in the investigator's centre) and muscle relaxation (suxamethonium) to prevent adverse events, ECT can be challenging for the anaesthesiologist, as it usually leads to rapid cardiovascular changes such as sudden bradycardia due to vagal discharge, followed by sympathetic counter regulation associated with tachycardia and hypertension. For the patient, known immediate side effects are headache in about 30% and postictal confusion and delirium in up to 65%. This confusional state can lead to involuntary movements and agitation and therefore be harmful for patients and attending staff. It usually resolves within 45 minutes but nevertheless seems to be linked with adverse side effects like persistent retrograde amnesia. Identified risk factors are long seizure time and pre-existing catatonic features. Postictal delirium has been classified by Kikuchi et. al. into four categories from no delirium, mild, moderate or severe delirium. Moderate to severe delirium needing restraints or sedative medication like benzodiazepines or Propofol was present 36% of patients, which is in line with older data. The more severe forms of delirium are easily recognised in clinical practice because of the need for intervention. When including mild forms, delirium was present in 52% of all patients in the study of Kikuchi et al. In newer studies using a more sensitive tool (CAM-ICU, Confusion Assessment Method - Intensive Care Unit) to assess the presence of delirium, the rates are up to 65% at 10 minutes after ECT stimulation respectively 10 minutes after arrival in the post-anaesthesia care unit. CAM-ICU is a brief but sensitive test, which has been extensively validated in the intensive care setting. Therefore, it seems that postictal delirium is frequently underdiagnosed in clinical practice. As we know from the intensive care literature, even hypoactive forms of delirium are associated with higher complication rates and higher mortality and therefore cannot be neglected.
In previous small studies, premedication with promethazine, midazolam and dexmedetomidine successfully reduced incidence of postictal delirium. Dexmedetomidine, a highly selective, relatively short acting alpha2-agonist, has been more extensively studied in the setting of ECT and has recently been able to show his potency to reduce postictal delirium by a third when given as a bolus pre-induction in a randomised controlled trial.
In this prospective, randomised, placebo-controlled, triple-blind, single-centre, two-arm parallel groups superiority trial, the investigators aim to lower incidence and severity of postictal delirium and agitation using a pre-induction dose of 2 mcg/kg clonidine intravenously compared to placebo (sodium chloride). The investigators also hypothesise, that a pre-induction dose of clonidine will reduce incidence of postictal agitation, the need for sedative rescue medication and the need for short-acting antihypertensive medication. It therefore might increase patient safety and cost effectiveness without prolonging post-anaesthesia care unit stay or negatively affecting treatment efficacy.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Christian M Beilstein, MD
- Phone Number: +41 31 632 24 82
- Email: Christian.Beilstein@insel.ch
Study Contact Backup
- Name: Patrick Y Wüthrich, Prof, MD
- Phone Number: +41 31 632 24 81
- Email: Patrich.Wuethrich@insel.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Recruiting
- Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern
-
Contact:
- Christian M Beilstein, MD
- Phone Number: +41 31 632 24 83
- Email: Christian.Beilstein@insel.ch
-
Contact:
- Patrick Y Wüthrich, Prof, MD
- Phone Number: +41 31 632 24 83
- Email: Patrick.Wuethrich@insel.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 and more;
- Scheduled for an elective series of ambulatory ECT sessions at the University Hospital Bern;
- Informed Consent as documented by signature (Appendix Informed Consent Form).
Exclusion Criteria:
- Contraindications to the study drug, e. g. known allergy or hypersensitivity, hypotension, bradycardia, higher grade atrioventricular block;
- On regular Clonidine for another indication (e.g. arterial hypertension)
- Patients undergoing emergency ECT;
- Unable to consent (incapable of judgment, next-of-kin consent necessary or under tutelage);
- Inability to follow the procedures of the study, e. g. due to language barrier;
- Previous enrolment into the current study;
- Participation in another study with investigational drug within the 30 days preceding and during the present study;
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
- Women who are pregnant or breast feeding;
- Intention to become pregnant during the course of the study;
- Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration (and 4 weeks thereafter), such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study. At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied. The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia. Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction. |
Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
Other Names:
|
Placebo Comparator: Control
The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application.
The container will be identically labelled as the verum.
The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing.
All other parts of the procedure are identical as to the procedure described above.
|
Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of delirium after electroconvulsive therapy over all (twelve) ECT sessions
Time Frame: 20 minutes after muscle relaxation
|
The primary outcome is delirium after electroconvulsive therapy over all (twelve) ECT sessions.
The presence of delirium will be assessed using Confusion Assessment Method - Intensive Care Unit (CAM-ICU).
To be able to perform the test correctly, the patient must be awake enough.
This will be assessed using the Richmond-Agitation-Sedation-Scale (RASS) first ranging from -5 (unarousable) to +4 (combative)
|
20 minutes after muscle relaxation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of mild agitation
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
RASS +1, needing verbal command or short restraint < 1 minute
|
post-anaesthesia care unit stay (up to 2 hours)
|
Incidence of severe agitation
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
RASS > 1, needing restraint > 1 minute or rescue medication)
|
post-anaesthesia care unit stay (up to 2 hours)
|
Use of rescue medication
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
medication, dose, route
|
post-anaesthesia care unit stay (up to 2 hours)
|
Duration of seizure activity
Time Frame: during procedure (estimated to be on average 10-15 minutes)
|
seconds
|
during procedure (estimated to be on average 10-15 minutes)
|
Quality of seizure activity
Time Frame: during procedure (estimated to be on average 10-15 minutes)
|
ideal, sufficient, insufficient
|
during procedure (estimated to be on average 10-15 minutes)
|
Seizure Quality Index
Time Frame: during procedure (estimated to be on average 10-15 minutes)
|
Seizure Quality Index (Kranaster et al., Eur Arch Psychiatry Clin Neurosci 2018) ranging from 0 to 5. Higher index indicates better response to treatment.
|
during procedure (estimated to be on average 10-15 minutes)
|
Need for seizure terminating medication
Time Frame: during procedure (estimated to be on average 10-15 minutes)
|
medication, dose, route
|
during procedure (estimated to be on average 10-15 minutes)
|
Total number of electroconvulsive therapy sessions
Time Frame: whole treatment course (12 ECT sessions, about 4 weeks)
|
number
|
whole treatment course (12 ECT sessions, about 4 weeks)
|
Reason for terminating or continuing the electroconvulsive series
Time Frame: whole treatment course (12 ECT sessions, about 4 weeks)
|
failure, response, remission, other reason
|
whole treatment course (12 ECT sessions, about 4 weeks)
|
Length of post-anaesthesia care unit stay
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
minutes
|
post-anaesthesia care unit stay (up to 2 hours)
|
Incidence of desaturation
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
Oxygen saturation by pulse oximetry < 75%, irrespective of duration
|
post-anaesthesia care unit stay (up to 2 hours)
|
Incidence of hypotension
Time Frame: during procedure (estimated to be on average 10-15 minutes)
|
any measurement with mean arterial pressure < 55 mmHg
|
during procedure (estimated to be on average 10-15 minutes)
|
Incidence of bradycardia
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
heart rate < 50 bpm for more than 1 minute
|
post-anaesthesia care unit stay (up to 2 hours)
|
Cardiovascular changes needing intervention
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
number and type
|
post-anaesthesia care unit stay (up to 2 hours)
|
Use of cardiovascular medication
Time Frame: post-anaesthesia care unit stay (up to 2 hours)
|
medication, dose, route
|
post-anaesthesia care unit stay (up to 2 hours)
|
Adverse events potentially attributable to ECT
Time Frame: whole treatment course (12 ECT sessions, about 4 weeks)
|
diagnosis
|
whole treatment course (12 ECT sessions, about 4 weeks)
|
Adverse events potentially attributable to Study Drug
Time Frame: whole treatment course (12 ECT sessions, about 4 weeks)
|
diagnosis
|
whole treatment course (12 ECT sessions, about 4 weeks)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Patrick Y Wüthrich, Prof, MD, Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Bipolar and Related Disorders
- Depressive Disorder
- Delirium
- Bipolar Disorder
- Depressive Disorder, Major
- Catatonia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
Other Study ID Numbers
- BECD-3-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Clonidine
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
-
OnxeoSimbec ResearchCompletedHealthyUnited Kingdom
-
Salem Anaesthesia Pain ClinicCompletedPain, Chronic | Insomnia ChronicCanada
-
Uwakwe Emmanuel ChijiokeRecruiting
-
Fred Hutchinson Cancer CenterInstitute for the Development of AfricaCompletedHIV Infections | HIV-1 and HSV-2 CoinfectionCameroon
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Afshan B. Hameed, M.D.Withdrawn
-
OnxeoCompletedOral MucositisSpain, United States, France, Germany, Hungary, Switzerland
-
Addrenex Pharmaceuticals, Inc.CompletedAttention Deficit Disorder With HyperactivityUnited States
-
The University of Texas Health Science Center,...CompletedWithdrawal; Therapeutic SubstanceUnited States